Ruby Chan Email and Phone Number

- Lead a discovery team that specializes in autologous and allogeneic cell therapies for both hematological and solid tumors.- Collaborate with cross-functional teams to integrate learnings from clinical trials and data science to improve next-generation cell therapy designs.- Distill complex problems and hypotheses into simple actionable solutions.

- Discovery lead in cell therapy programs- Specialized in off-the-shelf allogeneic NK and T cell therapies- Completed 2 NME's and 1 IND application

- Immuno-Oncology Biology lead in Compound Development Teams.- Provided project leadership in biologics, small molecule, and cell therapy programs.- Oversaw generation of in vitro and in vivo pharmacology data packages for NME and IND.- Designed and executed non-human primate studies and mouse tumor model studies to understand mechanisms of action of lead compounds.- Designed and validated rational combinations of IO therapeutics.

- Highly proficient in cellular and molecular immunology techniques, in vitro and ex vivo T cell, B cell, and dendritic cell/macrophage functional assays, and immunoprofiling of human and mouse biospecimens. - Collaborated across functional areas to effectively advance discovery and translational research programs in immuno-oncology.- Trained and mentored scientists, post-docs, research associates and interns in highly matrixed environment. - Led discovery team in due diligence process.

- Validated novel therapeutic targets for the treatment of hormonal therapy-resistant human breast cancer.- Demonstrated that inhibiting the critical Prolactin-JAK2-STAT3/5 signaling pathway using a small molecule JAK2 inhibitor led to regression of hormonal therapy-resistant tumors.

- Identified mechanism of tumorigenesis of estrogen receptor-positive breast cancer and the signaling pathway that mediated resistance to endocrine treatment.

Developed a unique, physiologically relevant model of human estrogen receptor-positive breast cancer.